Prot #GOG-3003: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF VTX-2337 (IND #78,416) IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITO

Project: Research project

Project Details

StatusFinished
Effective start/end date7/9/13 → 7/9/16

Funding

  • Gynecologic Oncology Group (Prot #GOG-3003 // Prot #GOG-3003)
  • VentiRx Pharmaceuticals, Inc. (Prot #GOG-3003 // Prot #GOG-3003)